Clinical Trial Update: Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov entry describes a Phase 3 trial evaluating an interleukin-6 receptor inhibitor for symptomatic intracranial atherosclerosis. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Infarction
• Intracranial Atherosclerosis
• Stroke

Drugs mentioned

• Unspecified interleukin-6 receptor inhibitor (Interleukin-6 receptor inhibitor)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Brain Diseases, Ischemic Stroke | Phase 3 | Status: NOT_YET_RECRUITING